Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Well said Florida - exactly right. It was this future vision that kept me here. Steven Little has had his detractors but they don't seem to appreciate his determination, in the face of daunting litigation, to drive us forward.
It was also his realization that he needed help to move us on and so Lyn Rees was brought on board - pretty much a master stroke for me. You've only got to see the both the revenue growth and the product diversification in just a couple of years or so. This company is on the cusp of solid long term growth.
Good post Florida. I generally agree but think that "all alternate NIPT products will eventually become obsolete, leaving us an open market" might just be a daydream too far. I would not complain though if it eventually came to pass.
For myself, I think if we manage to nab between 4-5% of the world market within approx 5-7 years would leave us all with a very very tidy profit.
No fly's on this one Threeskins. I would be very much surprised if Covid 19 had no detrimental effect whatsoever. However, i am secure in the fact that our core product is the backbone of the company and the driving force for growth. Aside all other products, IONA sales should, imv be unhindered to a large extent by the virus and we should not detract from the main objective to establish the IONA test as the unrivalled standard throughout the world. The present rate of growth for this product alone is astonishing to say the least, and I am particularly interested in where the numbers will be when fully established in the states. The solidity of the pace of growth can be judged by looking back at how fast we acquired new contracts at a time of heavy bombardment, under immense pressure exerted by Illumina's litigation. We tend to forget the main preset concept and goal that was established in the mind of Steven little long before Premaitha. He realised he had a product that could not be superseded and would at some point be the world standard. This in tern means that all alternate NIPT products will eventually become obsolete, leaving us an open market.
"The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period."